3 RESULTS
The screening was performed in 431 patients treated for hematological malignancies. Forty-five patients who fulfilled the study criteria were enrolled and are discussed henceforth. The characteristics of the 45 patients are listed in Table 1. The median duration from the end of treatment was 15 months (IQR 8.75, 25). The median duration since the last transfusion was 33 months (IQR: 23.5, 47.5). The patients treated with more intensive chemotherapy (regimen B for ALL) had a greater (8.9 vs. 7.9 units) transfusion requirement as compared to those treated with standard (regimen A for ALL) chemotherapy, though it lacked significance (p=0.066).